3月14日 - ** 药物开发商AltimmuneALT.O股价盘前上涨4.62%至5.44美元
** 该公司周四表示，它计划在 (link)，测试其肥胖症实验药物培伐度肽，以治疗酒精使用障碍和酒精相关肝病。
** 预计将在第二季度开始酒精使用障碍的中期研究，第三季度开始酒精相关肝病的中期研究
** 经纪商 Evercore ISI 称，这将为培美度肽的故事增加新的内容，ALT 可以在其中发挥主导作用
** 股价在过去 12 个月中下跌了约 52
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.